Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia

Schizophrenia Research

Volumn 80, Issue 2-3, 2005, Pages 315-322

  Nilsson, L K ^a   Linderholm, K R ^a   Engberg, G ^a   Paulson, L ^b   Blennow, K ^b   Lindstrom L H ^c   Nordin, C ^d   Karanti, A ^b   Persson, P ^e   Erhardt, S ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

^e Norra Älvsborgs Läns Landsting ^*  (Sweden)

Author keywords

Cerebrospinal fluid; Glutamate; Kynurenic acid; Schizophrenia

Indexed keywords

KYNURENIC ACID; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; KYNURENIC ACID; MALE; MIDDLE AGED; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 28244440276     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.07.013     Document Type: Article

References (41)

1. A. Abi-Dargham, J. Rodenhiser, D. Printz, Y. Zea-Ponce, R. Gil, L.S. Kegeles, R. Weiss, T.B. Cooper, J.J. Mann, R.L. Van Heertum, J.M. Gorman, and M. Laruelle From the cover: increased baseline occupancy of D2 receptors by dopamine in schizophrenia Proc. Natl. Acad. Sci. U. S. A. 97 2000 8104 8109
2. G.W. Albers, W.M. Clark, R.P. Atkinson, K. Madden, J.L. Data, and M.J. Whitehouse Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke Stroke 30 1999 508 513
3. H. Baran, N. Cairns, B. Lubec, and G. Lubec Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome Life Sci. 58 1996 1891 1899
4. H. Baran, K. Jellinger, and L. Deecke Kynurenine metabolism in Alzheimer's disease J. Neural Transm. 106 1999 165 181
5. P.A. Berger, K.F. Faull, J. Kilkowski, P.J. Anderson, H. Kraemer, K.L Davis, and J.D. Barchas CSF monoamine metabolites in depression and schizophrenia Am. J. Psychiatry 137 1980 174 180
6. P.J. Birch, C.J. Grossman, and A.G. Hayes Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor Eur. J. Pharmacol. 154 1988 85 87
7. L. Bjerkenstedt, G. Edman, L. Hagenfeldt, G. Sedvall, and F.A. Wiesel Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls Br. J. Psychiatry 147 1985 276 282
8. A. Carlsson The current status of the dopamine hypothesis of schizophrenia Neuropsychopharmacology 1 1988 179 186
9. A. Carlsson, and M. Lindqvist Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain Acta Pharmacol. Toxicol. 20 1963 140 144
10. A. Carlsson, N. Waters, S. Holm-Waters, J. Tedroff, M. Nilsson, and M.L. Carlsson Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence Annu. Rev. Pharmacol. Toxicol. 41 2001 237 260
11. S. Erhardt, and G. Engberg Increased phasic activity of dopaminergic neurons in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid Acta Physiol. Scand. 175 2002 45 53
12. S. Erhardt, K. Blennow, C. Nordin, E. Skogh, L.H. Lindström, and G. Engberg Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia Neurosci. Lett. 13 2001 96 98
13. S. Erhardt, H. Öberg, J.M. Mathé, and G. Engberg Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons Naunyn Schmiedeberg's Arch. Pharmacol. 20 2001 353 362
14. E.D. French Phencyclidine and the midbrain dopamine system: electrophysiology and behavior Neurotoxicol. Teratol. 16 1994 355 362
15. E.D. French, A. Mura, and T. Wang MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists Synapse 13 1993 108 116
16. S. Fukui, R. Schwarcz, S.I. Rapoport, Y. Takada, and Q.R. Smith Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism J. Neurochem. 56 1991 2007 2017
17. A.H. Ganong, and C.W. Cotman Kynurenic acid and quinolinic acid act at N-methyl-d-aspartate receptors in the rat hippocampus J. Pharmacol. Exp. Ther. 236 1986 293 299
18. J.B. Gramsbergen, W. Schmidt, WA. Turski, and R. Schwarcz Age-related changes in kynurenic acid production in rat brain Brain Res. 588 1992 1 5
19. J. Grotta, W. Clark, B. Coull, L.C. Pettigrew, B. Mackay, L.B. Goldstein, I. Meissner, D. Murphy, and L. LaRue Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial Stroke 26 1995 602 605
20. M.P. Heyes, and B.J. Quearry Quantification of kynurenic acid in cerebrospinal fluid: effects of systemic and central l-kynurenine administration J. Chromatogr. 530 1990 108 115
21. C. Hilmas, E.F. Pereira, M. Alkondon, A. Rassoulpour, R. Schwarcz, and E.X. Albuquerque The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications J. Neurosci. 21 2001 7463 7473
22. D.C. Javitt Glutamate as a therapeutic target in psychiatric disorders Mol. Psychiatry 9 2004 984 997
23. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am. J. Psychiatry 148 1991 1301 1308
24. J.D. Jentsch, and R.H. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225
25. M. Kessler, T. Terramani, G. Lynch, and M. Baudry A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists J. Neurochem. 52 1989 1319 1328
26. J.S. Kim, H.H. Kornhuber, W. Schmid-Burgk, and B. Holzmuller Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia Neurosci. Lett. 20 1980 379 382
27. L.H. Lindström Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history Psychiatry Res. 14 1985 265 273
28. C.L. Miller, I.C. Llenos, J.R. Dulay, M.M. Barillo, R.H. Yolken, and S. Weis Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia Neurobiol. Dis. 15 2004 618 629
29. F. Moroni, P. Russi, V. Carla, and G. Lombardi Kynurenic acid is present in the rat brain and its content increases during development and aging processes Neurosci. Lett. 94 1988 145 150
30. B.J. Morris, S.M. Cochran, and J.A. Pratt PCP: from pharmacology to modelling schizophrenia Curr. Opin. Pharmacol. 5 2005 101 106
31. N. Müller, M. Riedel, C. Scheppach, B. Brandstatter, S. Sokullu, K. Krampe, M. Ulmschneider, R.R. Engel, H.J. Moller, and M.J. Schwarz Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia Am. J. Psychiatry 159 2002 1029 1034
32. N. Müller, M. Riedel, and M.J. Schwarcz Psychotropic effects of COX-2 inhibitors-a possible new approach for the treatment of psychiatric disorders Pharmacopsychiatry 37 2004 266 269
33. Nilsson, L.K., Linderholm, K.R., Erhardt, S., in press. Subchronic treatment with kynurenine and probenecid; Effects on prepulse inhibition and firing of midbrain dopamine neurons. J. Neural Transm. (Electronic publication ahead of print; doi:10.1007/s00702-005-0343-z ).
34. H. Nybäck, B.M. Berggren, T. Hindmarsh, G. Sedvall, and F.A. Wiesel Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers Psychiatry Res. 9 1983 301 308
35. C.G. Parsons, W. Danysz, G. Quack, S. Hartmann, B. Lorenz, C. Wollenburg, L. Baran, E. Przegalinski, W. Kostowski, P. Krzascik, B. Chizh, and P.M. Headley Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization J. Pharmacol. Exp. Ther. 283 1997 1264 1275
36. T. Persson, and B.E. Roos Acid metabolites from monoamines in cerebrospinal fluid of chronic schizophrenics Br. J. Psychiatry 115 1969 95 98
37. R.M. Post, E. Fink, W.T. Carpenter Jr., and F.K. Goodwin Cerebrospinal fluid amine metabolites in acute schizophrenia Arch. Gen. Psychiatry 32 1975 1063 1069
38. R. Schwarcz, A. Rassoulpour, H-Q. Wu, D. Medoff, C.A. Tamminga, and R.C. Roberts Increased cortical kynurenate content in schizophrenia Biol. Psychiatry 50 2001 521 530
39. L. Schwieler, S. Erhardt, C. Erhardt, and G. Engberg Prostaglandin- mediated control of rat brain kynurenic acid synthesis-opposite actions by COX-1 and COX-2 isoforms J. Neural Transm. 112 2005 863 872
40. G. Sedvall, B. Fyro, B. Gullberg, H. Nybäck, F.A. Wiesel, and B. Wode-Helgodt Relationships in healthy volunteers between concentrations of monoamine metabolites in cerebrospinal fluid and family history of psychiatric morbidity Br. J. Psychiatry 136 1980 366 374
41. I.M. Wieselgren, and L.H. Lindström CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia Psychiatry Res. 81 1998 101 110